• Home
  1. Home
  2. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer
Scientific article
English

Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer

Contributors

Husarik, Daniela B.; Miralbell, Raymond; Dubs, Markus; John, Hubert; Giger, Olivier T.; Gelet, Albert; Cservenyàk, Tibor; Hany, Thomas F.

Published in

European journal of nuclear medicine and molecular imaging, vol. 35, no. 2, p. 253-263

Publication date

2008

Abstract

PURPOSE: To evaluate the accuracy of [(18)F]-choline (FCH) positron emission tomography/computed tomography (PET/CT) for staging and restaging of prostate cancer. METHODS: FCH PET/CT was performed in 111 patients with prostate cancer using 200 MBq FCH: 43 patients [mean age 63 years; mean prostrate specific antigen (PSA) 11.58 microg/l] were examined for initial staging, and 68 patients (mean age 66.4 years) were examined for restaging (mean PSA 10.81 microg/l). FCH PET/CT results were correlated to histopathology, bone scan, morphology as revealed by magnetic resonance imaging (MRI) and CT, PET/CT follow-up and PSA follow-up after therapy. RESULTS: FCH PET/CT scans at initial staging correctly showed no metastases in 36/38 patients undergoing radical surgery, as confirmed by PSA levels <0.1 microg/l 6 months postoperatively. Lymphadenectomy was performed in 24 of these patients, revealing four false FCH-negative lymph nodes (LN). In one patient, only lymphadenectomy was performed since a FCH-positive LN was confirmed by histology. Four patients showed FCH-positive bone metastases, as proven by bone scan. FCH PET/CT scans at restaging correctly revealed local recurrence in 36 patients. No pathological FCH uptake was observed in 11 patients with biochemical recurrence. Twenty-three patients showed FCH-positive LN. Twenty LN were surgically removed in seven patients. Histopathology verified metastases in all LN, but revealed two additional metastastic, FCH-negative LN. Seventeen patients showed FCH-positive bone metastases, as proven by bone scan or MRI. Sensitivity to detect recurrent disease was 86%. CONCLUSION: The results obtained using FCH PET/CT scans for initial N-staging were discouraging, especially in terms of its inability to detect small metastases. Recurrent disease can be localized reliably in patients with PSA levels of >2 microg/l.

Keywords

  • Aged
  • Choline/diagnostic use
  • Fluorine Radioisotopes/diagnostic use
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Positron-Emission Tomography/methods
  • Prostatic Neoplasms/diagnosis
  • Radiopharmaceuticals/diagnostic use
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Tomography, X-Ray Computed/methods

UNIGE affiliation entities

UNIGE research groups

Citation (ISO format)

HUSARIK, Daniela B. et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. In: European journal of nuclear medicine and molecular imaging, 2008, vol. 35, n° 2, p. 253–263. doi: 10.1007/s00259-007-0552-9

Main files (1)

Article (Accepted version)

Identifiers

Additional URL for this publication

http://www.springerlink.com/content/63035x432h0l7277/

Journal ISSN

1619-7070
655views
0downloads

Technical informations

Creation

10/08/2009 12:32:00

First validation

10/08/2009 12:32:00

Update

14/03/2023 15:10:13

Status update

14/03/2023 15:10:13

Last indexation

29/10/2024 11:52:04
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated